Pharma BD Deal Intelligence
Chiesi to acquire Amryt Pharma for $14.50/ADS plus CVR total up to $1.48 billion.
Amryt 6-K: CVR Agreement milestones achieved as of 18 December 2023; payment to CVR holders to be made per the CVR Agreement.
Chiesi Global Rare Diseases revenue rose ~41% to EUR 763M in 2024, driven by full integration of Amryt Pharma and new US product launches.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Chiesi Farmaceutici acquired Amryt Pharma for $14.50 per share (~$1.47 billion), gaining a rare disease portfolio led by Filsuvez (birch triterpenes) for epidermolysis bullosa and Myalept (metreleptin) for lipodystrophy. The deal closed April 6, 2023 and included contingent value rights (~$220M) tied to a U.S. Filsuvez approval. That milestone was achieved: the FDA approved Filsuvez for junctional and dystrophic epidermolysis bullosa (patients 6 months and older) on December 19, 2023, triggering the contingent payment and validating the deal thesis. Amryt assets were folded into Chiesi Global Rare Diseases, which reported sharply higher rare disease revenue in 2024 driven by the integration.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Chiesi Farmaceutici S.p.A. / Amryt Pharma plc (this deal) | 2023 | $1.5B | 72 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| LEO Pharma A/S / AstraZeneca PLC | 2016 | $1.1B | 80 |
← Browse all deals · How we score deals
More: 2023 deals · Dermatology deals